Investor Relations

• making recommendations to the Board on the appointment, reappointment and removal of external auditors, approving the remuneration and terms of engagement of external auditors, and dealing with any issues in relation to resignation or dismissal of external auditors；

• reviewing and monitoring external auditors’ independence and objectivity and the effectiveness of the audit process in accordance with applicable standards, discussing with auditors on the nature and scope of the audit work and reporting obligations before the audit commences;

• developing and implementing policies with respect to the non-audit work provided by external auditors;

• examining the completeness of the Group’s financial statements and the Group’s quarterly, interim and annual reports, and reviewing critical   financial reporting judgments contained therein;

• overseeing the Group’s financial reporting, risk management and internal control systems;

• managing matters related to connected transactions;

• reviewing and approving the Group’s connected transactions and other related matters to the extent authorized by the Board;

• formulating, monitoring and overseeing the anti-corruption and anti-bribery policies and systems of the Group;

• formulating, monitoring and overseeing the whistle-blowing policies and systems of the Group; and

• providing information for the independent non-executive Directors and auditors to perform their annual review of the connected transactions

• making recommendations to the Board on the compensation remuneration packages of individual executive Directors and senior management and on the compensation of non-executive Director;

• making recommendations to the Board on the management’s remuneration proposals;

• ensuring that no Director or any of his/her associates is involved in deciding his/her own remuneration;

• developing policies and structure for remuneration of all Directors, senior management and employees including salaries, incentive schemes and other share schemes, and making recommendations to the Board; and

• reviewing and/or approving matters relating to share schemes under Chapter 17 of the Listing Rules, including any grants of options or awards to directors, senior management, consultants and employees and making disclosure and giving explanation on the appropriateness to such material matters (if any) being approved in the corporate governance report.

• reviewing the structure, size and composition of the Board at least annually and making recommendations on any proposed changes to the Board to complement the Company’s corporate strategy;

• identifying individuals suitably qualified to become Board members and making recommendations to the Board;

• assessing the independence of independent non-executive Directors;

• making recommendations to the Board on the appointment and succession planning of Directors

• reviewing the diversification policy and its implementation on an annual basis, developing and reviewing measurable objectives for implementing the diversification policy and monitoring the progress on achieving these objectives;

• formulating and reviewing the policy for the nomination of directors which includes the nomination process and the criteria;

• formulating and reviewing on an annual basis the mechanism to ensure independent views and inputs are available to the Board; and

• reviewing and monitoring the training and continuous professional development of directors, coordinating with the Company for arranging appropriate trainings with appropriate focus on the roles, functions and responsibilities of director.

• reviewing and making recommendations to the Board on the long-term strategic development plans of the Company;

• reviewing and making recommendations to the Board in relation to any significant capital operations (including but not limited to the alternation of the registered issued share capital; issuance of bonds or other securities; the merger, separation, dissolution or transformation of company structure of the Company or any of its wholly owned or holding subsidiaries; the Company’s profit distribution plan and plans for loss recovery), asset management projects, the Company’s annual financial budget plan, and final accounts;

• reviewing and making recommendations to the Board on any financing investment projects relating to issuance of securities by the Company or any of its wholly owned or holding subsidiaries;

• reviewing the Group’s major investment and financing proposals in accordance with the Amended and Restated Articles of Association and overseas investment management measures, and making recommendations to the Board;

• making recommendations to the Board on any major matters that would affect the Company’s development;

• implementing and supervising the above items, reviewing, evaluating and making recommendations on any major changes made to these items, for the Board’s approval;

• developing the Company’s ESG objectives, strategies and structure, reviewing the progress in achieving the Company’s ESG objectives, and making recommendations to the Board on relevant ESG work in line with the Company’s strategic development;

• reviewing ESG-related issues that have a significant impact on the Company’s operations and/or the interests of other key stakeholders;

• considering the Company’s assessment of its environmental and social impact, and reviewing international and China’s ESG trends, in order to ensure the effective assessment of potential impact, opportunities and risks to the Company’s business;

• monitoring the implementation of the Company’s ESG policies and strengthening process control to ensure that the sustainability and effectiveness of the relevant actions in compliance with applicable laws and regulatory requirements;

• referring to key ESG reporting guidance for the relevant industry or sector, and to widely consider suggestions from stakeholders or to seek independent assurance verification by third parties in order to strengthen the scientific management of ESG and the credibility of ESG information disclosure;

• making timely, accurately and complete information disclosure under the requirements of the Listing Rules, the CG Code (set out in Appendix 14 to the Listing Rules) and the Environmental, Social and Governance Reporting Guide (set out in Appendix 27 to the Listing Rules); and

• other matters authorized by the Board.

Dr. Jincai LI (李錦才)

Dr. Li, aged 53, is an executive Director and chairman of the Board. He is primarily responsible for formulating overall strategic plans, business development and daily operations of the Group. Dr. Li has over 20 years of experience in biologics process development, scale up and cGMP manufacturing (current good manufacturing practice). He has been a director of WuXi XDC since its incorporation in December 2020, and has been re-designated as an executive director and appointed as the chief executive officer of WuXi XDC since June 2023. Under his leadership, WuXi XDC became a leading antibody drug conjugate (“ADC”) and bioconjugates contract research, development and manufacturing organization (“CRDMO”), which was recognised by the 2022 World ADC Awards’ Runner Up prize in the “Best CMO Provider” category and the winner of the 2023 World ADC Awards’ prize in the “Best Contract Development Manufacturing Organization (CDMO)” category. 

Dr. Li joined WuXi Biologics (Cayman) Inc. (together with its subsidiaries, “WXB Group”) in September 2011 and has served as the senior vice president at the WXB Group since May 2020. Before Dr. Li joined the WXB Group, from August 2007 to September 2011, Dr. Li had served as a group leader at Genentech, Inc. where he was responsible for cell culture process development. From April 2006 to July 2007, Dr. Li was a scientist at Tanox, Inc., and from August 2001 to March 2006, Dr. Li was a staff scientist at Diversa Corporation (now BASF) where he was in charge of process development for multiple biologics projects. 

Dr. Li obtained a bachelor’s degree in chemical engineering and technology and minor in chemistry from Tsinghua University in the People’s Republic of China (the “PRC”) in July 1996. Dr. Li then obtained a doctoral degree majoring in chemical and biochemical engineering from University of Maryland Baltimore County in the United States in August 2001.

Mr. Xiaojie XI (席曉捷)

Mr. Xi, aged 50, is a non-executive Director. Mr. Xi is primarily responsible for overseeing the overall financial management, financial matters and strategic development of the Group. Mr. Xi has been an executive director of WuXi XDC since June 2023 and the chief financial officer and company secretary of WuXi XDC since May 2023 and November 2023, respectively. He brings over 20 years of financial industry experience in the United States and the PRC, including investment banking and private equity investment with many public and private companies. 

Prior to joining WuXi XDC, from November 2018 to May 2023, Mr. Xi had served as the chief financial officer and simultaneously from April 2020 to May 2023, a joint company secretary of Akeso, Inc. (HKEX: 09926). Before that, from August 2017 to October 2018, he was a director at SIN Capital (HK) Limited, focusing on investments in the healthcare industry in China, and from April 2015 to July 2017, he served as a director of corporate finance and capital markets at CLSA Limited. Between October 2013 and April 2015, Mr. Xi was the vice president of investment banking and strategic advisory department at Credit Suisse AG(Hong Kong branch). From March 2010 to April 2013, Mr. Xi served as the vice president of investment banking division at Morgan Stanley Asia Limited. During his time with the aforementioned investment banks, Mr. Xi had executed high profile transactions, including IPOs, debt and equity financings and M&As for leading companies in China. 

Mr. Xi obtained his bachelor’s degree in biochemistry from Wuhan University in the PRC in 1997 and obtained his master’s degree in science from Rutgers, The State University of New Jersey in the United States in 2002. He then completed his Master’s degree in business administration with distinction at New York University, Stern School of Business in the United States in 2008.

Mr. Xin FAN (樊欣)

Mr. Fan, aged 47, is an independent non-executive Director. Mr. Fan is primarily responsible for supervising and providing independent judgment to the board of the Group. Mr. Fan has served as the chief financial officer of Bilibili Inc.  (Nasdaq: BILI; HKEX: 9626) since September 2017. Prior to that, Mr. Fan had served as Bilibili Inc.’s vice president of finance since April 2016. Before joining Bilibili Inc., Mr. Fan served as a finance director at NetEase, Inc. (Nasdaq: NTES; HKEX: 9999) from 2011 to 2016. Prior to 2011, Mr. Fan held various positions at KPMG Huazhen LLP  for an aggregate of eight years and served as a senior manager there from 2008 to 2011. Mr. Fan has also served as an independent director of Sipai Health Technology Co., Ltd. (HKEX: 0314) since May 2023 and as an independent director of MicroPort NeuroScientific Corporation  (HKEX: 2172) since June 2024.

Mr. Fan received his bachelor’s degree in international accounting from Shanghai University of Finance and Economics in the PRC in 2001. Mr. Fan is a regular member of the American Institute of Certified Public Accountants and a certified public accountant in the PRC. He also holds licences as chartered global management accountant and chartered certified accountant in the United Kingdom.

Dr. Ulf GRAWUNDER

Dr. Grawunder, aged 61, is an independent non-executive Director. He is primarily responsible for supervising and providing independent judgment to the board of the Group. Dr. Grawunder is an experienced Swiss life-science entrepreneur with over 20 years of experience in the therapeutic antibody development industry. He has also been an independent non-executive director of WuXi XDC since November 2023 and Nasdaq-listed Adagene Inc. (ADAG), since April 2024.

Dr. Grawunder is a co-founder and, since 2022, has served as chief executive officer and initially Board member of T-CURX LLC in Germany, a German biotech company that focuses on the development of next-generation CAR-T cell therapies for cancer patients. Furthermore, since 2022, he is also managing partner of Viopas Venture Consulting LLC, Switzerland. Before that, from 2012 to 2021, Dr. Grawunder was the founder and chief executive officer of NBE-Therapeutics Ltd in Switzerland, a biotech company developing ADCs for cancer therapy, acquired by Boehringer Ingelheim, Germany in 2021. Dr. Grawunder began his industry career in 2003 by co-founding Swiss biotechnology company 4-Antibody Ltd, developing therapeutic antibodies in autoimmunity and oncology, where from 2006 to 2012 he initially served as chief executive officer and later as the chief scientific officer, until the company was sold to US-based, Nasdaq-listed Agenus Inc. (AGEN).

Dr. Grawunder served as advisor to Swiss ADC biotech company, Araris Biotech, until its acquisition by Japanese pharmaceutical company Taiho Pharmaceutical in March 2025. Since 2026 Dr. Grawunder is advisor to Swiss ADC biotech company Clearidebio-Therapeutics. From 2010 to 2014 Dr. Grawunder was also Vice-president of the Swiss Biotech Association.

Dr. Grawunder obtained his bachelor’s degree in biochemistry in October 1988 and his master’s degree in biochemistry in July 1991, both from the University of Bayreuth, Germany. He subsequently obtained his doctoral degree in cell biology from the University of Basel in Switzerland in July 1994, followed by post-doctoral research in the U.S. at Washington University School of Medicine in St. Louis, MO, and University of Southern California in Los Angeles, CA, from 1995-1998. In addition, Dr. Grawunder holds a diploma in Technology Entrepreneurship from the University St. Gallen, School of Business, in Switzerland.

Dr. Chaohong HU (胡朝紅)

Dr. Hu, aged 60, is an independent non-executive Director. Dr. Hu is primarily responsible for supervising and providing independent judgment to the board of the Group. She has been an independent non-executive director of Hutchmed (China) Limited (HKEX: 0013) since 2024 and is currently the chief operating officer of D Biotherapeutics, LLC and an owner and principal consultant of Lakebio Consulting, LLC. She was previously the executive director and co-chief executive officer of Lepu Biopharma Co., Ltd.  (HKEX: 2157) from 2020 to January 2024. She was also chief executive officer and chairman of the board of Shanghai Miracogen Inc.  (“Shanghai Miracogen”), a company founded by Dr. Hu, focusing on the research and development, clinical study and industrialization of new drugs for targeted cancer therapy – ADCs, from 2014 to January 2024. She disposed of all her interests in Shanghai Miracogen in 2020. Prior to founding Shanghai Miracogen, Dr. Hu served as a director of the Bioassay Development and Process Analytics department at Seagen Inc. (previously listed on Nasdaq); director of the Molecular Biology and Clinical Immunology department of GlaxoSmithKline plc (currently GSK plc)  (LSE/NYSE: GSK); and research scientist and director of the Molecular Biology and Clinical Immunology department of ID Biomedical Corporation (previously listed on Nasdaq). She was also a post-doctoral fellow of the University of Washington.

Dr. Hu holds a Bachelor of Science degree in biochemistry from Wuhan University in the PRC and a PhD in molecular biology from Institute of Biophysics, Chinese Academy of Sciences in the PRC.